

SKINMEDICA AND GALDERMA TO CO-PROMOTE DESONATE(TM)

SkinMedica

PR Newswire, November 07, 2006

SkinMedica, Inc., a specialty pharmaceutical company focused on dermatology, announced an agreement with Galderma Laboratories, L.P. for the co-promotion of Desonate(TM) (desonide) Gel 0.05% for treatment of mild-to-moderate atopic dermatitis.

Desonate, developed in collaboration between SkinMedica and Dow Pharmaceutical

Sciences, Inc., is a low potency topical steroid formulated in Dow's proprietary water-based Hydrogel(TM) vehicle. The patented formula is free of alcohol, fragrance or surfactants that can be irritating or drying to the skin of atopic dermatitis patients.

SkinMedica will promote Desonate to the dermatology market while Galderma will promote Desonate to pediatricians via its highly specialized pediatric sales force.

"We are delighted to have a partner of Galderma's caliber supporting us in commercializing Desonate Hydrogel," said Rex Bright, President & CEO of SkinMedica. "Galderma's experience with the desonide molecule, their exceptional pediatric sales force and their leadership in commercializing topical products for dermatitis made them a natural choice for SkinMedica."

"This is an exciting addition to the portfolio of products in our pediatric division," said Albert Draaijer, President of Galderma U.S. "The formulation is ideal for the pediatric patient. It incorporates what we like to call 'Smart Science' in that it has the best of both worlds for the patient; an excellent cosmetically elegant vehicle, plus the proven safety and efficacy of the desonide molecule. We are very pleased with the potential that comes from this agreement with SkinMedica."

On October 23rd, SkinMedica announced the U.S. Food and Drug Administration (FDA) approval of the company's New Drug Application (NDA) for Desonate (desonide) Gel 0.05% for treatment of mild-to-moderate atopic dermatitis. Desonide is the leading low potency corticosteroid in the U.S. dermatology market with a long history of proven safety and efficacy. The safety and efficacy of Desonate was demonstrated in two Phase III clinical trials with a total of 582 mild-to-moderate atopic dermatitis subjects aged 3 months to 18 years. The results demonstrated a statistically significant treatment effect for Desonate compared to placebo in both primary and secondary endpoints.

The patented formula is designed to provide a comfortable, non-irritating, silky smooth feel that will not leave a greasy residue. In two pivotal clinical trials, application site burning and rash were reported by 1% and pruritus (itching) by less than 1% of all treated patients. The product is approved for use in children over three months of age and for adults who suffer from the chronic itching and inflammatory symptoms of atopic dermatitis, commonly known as eczema. The safety and efficacy of Desonate was established for up to 4 weeks of use, and the product is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation.